LifeLabs Medical Laboratory Services

LifeLabs Medical Laboratory Services

February 23, 2015 08:00 ET

LifeLabs Partners With Abbott and Roche Diagnostics to Set New Standards for World-Class Laboratory Technology

TORONTO, ONTARIO and VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 23, 2015) - LifeLabs is pleased to announce that it is partnering with Abbott and Roche Diagnostics to provide LifeLabs' chemistry testing across Canada. Chemistry tests are by far the largest area of diagnostic testing performed by LifeLabs. Chemistry tests, such as those that measure blood sugars and kidney function, provide vital information that may assist healthcare professionals diagnose and monitor the health of a patient. Once implemented, the LifeLabs, Abbott and Roche partnership will result in a chemistry testing platform that provides enhanced quality, functionality, automation and improved testing turn-around times.

"LifeLabs has a strong track record of delivering meaningful innovations that benefit patients, physicians and our health care partners," said Sue Paish, LifeLabs' President and Chief Executive Officer. "Through our partnership with Abbott and Roche, LifeLabs is investing in world-class technology that supports our commitment to deliver reliable, top-quality community lab testing to Canadians."

This will be the first time in North America that Roche and Abbott platforms are used together on a single laboratory automation system. Over the next two years, LifeLabs will work with Abbott and Roche to install state-of-the-art equipment at ten LifeLabs laboratories across Ontario and British Columbia.

"Abbott is committed to providing diagnostics solutions to help health care providers achieve faster and more accurate test results to improve patient care," said Jeremy Schubert, divisional vice president for Latin America and Canada, Diagnostics, Abbott. "By providing integrated diagnostic solutions, powered by innovations that can help customers, labs such as LifeLabs are able to channel change into growth and ensure exceptional performance for its entire organization."

Under the new agreement, the combined Abbott and Roche platforms will be used for high-volume chemistry, immunochemistry and infectious disease testing. An Abbott automation system will also be used to help LifeLabs maximize operational efficiencies and quality. The implementation of these technologies will standardize LifeLabs' chemistry platforms and deliver common, standard, high quality analytical test results to patients and health care providers, regardless of location.

"We are extremely delighted to be working with LifeLabs to showcase the power of our laboratory platforms," said Mr. Ian Parfrement, President and General Manager of Roche Diagnostics in Canada. "Our state-of-the-art throughput analyzers allow laboratories to greatly enhance their testing efficiency while at the same time delivering the highest quality patient results. With our solutions, LifeLabs will continue to provide the highest standard of patient care well into the future."

LifeLabs expects the new platforms to be fully operational at all its laboratories in both Ontario and British Columbia by late 2016.

About LifeLabs

LifeLabs is a Canadian-owned company with over 50 years of experience providing laboratory testing services to help healthcare providers diagnose, treat, monitor and prevent disease. In communities across British Columbia and Ontario, LifeLabs delivers cost-effective, convenient access to laboratory testing services which are essential for optimal outcomes in healthcare. LifeLabs employs approximately 5,400 professionally trained staff and delivers over 100 million laboratory tests, supporting 19 million patient visits annually. In 2013, LifeLabs acquired BC Biomedical in British Columbia and CML HealthCare in Ontario making LifeLabs the largest community laboratory in Canada. LifeLabs is indirectly owned by OMERS Administration Corporation, whose interest is managed by Borealis Infrastructure. For more information, please visit LifeLabs is a Proud Supporter of the TORONTO 2015 Pan Am/Parapan Am Games.

About Borealis Infrastructure

Borealis Infrastructure is a leader in direct infrastructure investing with over a decade of investment experience. Borealis manages more than $11 billion in OMERS equity capital through investments in a diversified portfolio of large-scale infrastructure assets exhibiting stability and strong cash flows, in sectors including energy, transportation and social infrastructure. It has offices in Toronto, London, New York and Sydney. Borealis is the infrastructure investment arm of OMERS, one of Canada's largest pension funds with net assets of more than $65 billion and an AAA credit rating. For more information please visit or

Contact Information